Europe Bladder Disorders Market
Taille du marché en milliards USD
TCAC : %
Période de prévision |
2022 –2029 |
Taille du marché (année de référence) |
USD 2,332.69 Million |
Taille du marché (année de prévision) |
USD 5,226.00 Million |
TCAC |
|
Principaux acteurs du marché |
>Marché européen des troubles de la vessie, par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle , cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire, autres), canal de distribution (direct, vente au détail) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché des troubles de la vessie en Europe
Les troubles de la vessie sont un groupe de troubles qui peuvent affecter les activités quotidiennes de la vie humaine. Certains des troubles de la vessie les plus courants sont la cystite, dans laquelle la vessie est infectée et provoque une inflammation. L'incontinence urinaire, dans laquelle la vessie est perdue, la cystite interstitielle, dans laquelle la vessie se met à uriner fréquemment et impérativement, et la vessie hyperactive , dans laquelle la vessie comprime l'urine. Les troubles de la vessie peuvent affecter la qualité de vie et causer d'autres problèmes de santé. Les changements et problèmes de santé, notamment les facteurs liés au système nerveux et au mode de vie, peuvent provoquer ou contribuer à l'IU chez les hommes et les femmes.
Les troubles de la vessie les plus courants sont l'hyperactivité vésicale et l'incontinence urinaire. Ces problèmes sont associés au système nerveux. Les nerfs transmettent des messages du cerveau à la vessie, indiquant que les muscles se contractent ou se relâchent.
Le marché européen des troubles de la vessie devrait croître au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 10,7 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 5 226,00 millions USD d'ici 2029 contre 2 332,69 millions USD en 2021.
Rapport métrique |
Détails |
Période de prévision |
2022 à 2029 |
Année de base |
2021 |
Années historiques |
2020 (Personnalisable 2019-2014) |
Unités quantitatives |
Chiffre d'affaires en millions USD |
Segments couverts |
Par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle, cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire, autres), canal de distribution (direct, vente au détail) |
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Pays-Bas, Russie, Suisse, Turquie, Autriche, Norvège, Hongrie, Lituanie, Irlande, Pologne, Reste de l'Europe |
Acteurs du marché couverts |
Les principales entreprises présentes sur le marché sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Urovant Sciences entre autres. |
Définition du marché des troubles de la vessie en Europe
Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, urinary incontinence - loss of bladder control, overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first-line of pharmacotherapy in overactive bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Europe Bladder Disorders Market Dynamics
Drivers
-
STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.
Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.
-
GROWING GERIATRIC POPULATION
Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.
According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.
-
RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.
-
COMBINATION OF DIFFERENT TARGET THERAPIES
Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.
Opportunities
-
SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.
Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.
Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.
-
RISING DISEASE MANAGEMENT PROGRAMS
People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems coupled with increasing healthcare expenditures has encouraged better healthcare plans.
Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.
Restraints/Challenges
However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.
This Bladder Disorders Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe Bladder Disorders Market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Europe Bladder Disorders Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market
Recent Development
- En février, AbbVie a annoncé l'approbation par la FDA américaine du BOTOX® pour le traitement de l'hyperactivité du détrusor (muscle de la vessie) associée à une affection neurologique chez les patients pédiatriques âgés de 5 ans. « Le BOTOX® est la première neurotoxine autorisée pour traiter l'hyperactivité neurogène du détrusor chez les enfants dont l'affection ne peut être traitée avec succès par un traitement anticholinergique. » Cette approbation augmentera le chiffre d'affaires de l'entreprise
Portée du marché européen des troubles de la vessie
Le marché européen des troubles de la vessie est segmenté en type, type de traitement, utilisateur final et canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance limités dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour prendre des décisions stratégiques afin d'identifier les principales applications du marché.
Taper
- Cystite
- Incontinence urinaire
- Vessie hyperactive
- Cystite interstitielle
- Cancer de la vessie
Sur la base du type, le marché européen des troubles de la vessie est segmenté en cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle et cancer de la vessie.
Type de traitement
- Chirurgie
- Médicaments
- Autres
Sur la base du produit, le marché européen des troubles de la vessie est segmenté en chirurgie, médicaments et autres
Utilisateur final
- Hôpital
- Cliniques
- Centres de chirurgie ambulatoire
- Autres
Sur la base des utilisateurs finaux, le marché européen des troubles de la vessie est segmenté en hôpitaux, cliniques, centres de chirurgie ambulatoire et autres
Canal de distribution
- Direct
- Vente au détail
Sur la base du canal de distribution, le marché européen des troubles de la vessie est segmenté en vente directe et au détail.
Analyse/perspectives régionales du marché des troubles de la vessie en Europe
Le marché européen des troubles de la vessie est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type, type de traitement, utilisateur final et canal de distribution, comme référencé ci-dessus.
Les pays couverts par ce marché sont l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne, la Turquie, la Russie, les Pays-Bas, la Suisse, la Belgique et le reste de l'Europe.
L'Allemagne domine le marché européen des troubles de la vessie en termes de part de marché et de chiffre d'affaires et continuera de renforcer sa domination au cours de la période de prévision. Cela est dû à la forte prévalence des troubles de la vessie hyperactive dans la région, et aux investissements croissants en R&D et au lancement de nouvelles thérapies qui stimulent le marché
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales et de l'impact des canaux de vente sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des troubles de la vessie en Europe
Le paysage concurrentiel du marché des troubles de la vessie en Europe fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que l'orientation de l'entreprise vers le marché européen des troubles de la vessie.
Français Certains des principaux acteurs opérant sur le marché européen des troubles de la vessie sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Urovant Sciences entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, l'Europe par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 EUROPE BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 EUROPE BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 EUROPE BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 EUROPE BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 EUROPE BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 EUROPE BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K.
11.1.3 FRANCE
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 TURKEY
11.1.7 RUSSIA
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 BELGIUM
11.1.11 REST OF EUROPE
12 EUROPE BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 EUROPE DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 EUROPE HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 23 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 31 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 37 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 43 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 49 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 50 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 55 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 56 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 67 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 68 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 73 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 80 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 85 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 86 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 87 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 88 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 89 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 EUROPE BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BLADDER DISORDERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE EUROPE BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE BLADDER DISORDER MARKET
FIGURE 14 EUROPE BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 15 EUROPE BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 23 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 25 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 26 EUROPE BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 27 EUROPE BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 EUROPE BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 31 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 32 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 35 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.